PE20210406A1 - Inhibidores de inflamasoma nlrp3 - Google Patents
Inhibidores de inflamasoma nlrp3Info
- Publication number
- PE20210406A1 PE20210406A1 PE2021000092A PE2021000092A PE20210406A1 PE 20210406 A1 PE20210406 A1 PE 20210406A1 PE 2021000092 A PE2021000092 A PE 2021000092A PE 2021000092 A PE2021000092 A PE 2021000092A PE 20210406 A1 PE20210406 A1 PE 20210406A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halo
- diseases
- triazin
- pyrrolo
- Prior art date
Links
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 108010034143 Inflammasomes Proteins 0.000 abstract 1
- 102000012064 NLR Proteins Human genes 0.000 abstract 1
- 108091005686 NOD-like receptors Proteins 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185580 | 2018-07-25 | ||
| EP19175246 | 2019-05-17 | ||
| PCT/IB2019/056278 WO2020021447A1 (en) | 2018-07-25 | 2019-07-23 | Nlrp3 inflammasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20210406A1 true PE20210406A1 (es) | 2021-03-02 |
Family
ID=67989037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000092A PE20210406A1 (es) | 2018-07-25 | 2019-07-23 | Inhibidores de inflamasoma nlrp3 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12168012B2 (https=) |
| EP (1) | EP3827008B1 (https=) |
| JP (1) | JP7555327B2 (https=) |
| KR (1) | KR20210038877A (https=) |
| CN (1) | CN112424207B (https=) |
| AU (1) | AU2019309727B2 (https=) |
| BR (1) | BR112021000964A2 (https=) |
| CA (1) | CA3103943A1 (https=) |
| CL (1) | CL2021000191A1 (https=) |
| CO (1) | CO2021000537A2 (https=) |
| CR (1) | CR20210045A (https=) |
| CU (1) | CU20210009A7 (https=) |
| DO (1) | DOP2021000019A (https=) |
| EC (1) | ECSP21004787A (https=) |
| IL (1) | IL280336A (https=) |
| JO (1) | JOP20210017A1 (https=) |
| MA (1) | MA53388A (https=) |
| MX (1) | MX2021000925A (https=) |
| PE (1) | PE20210406A1 (https=) |
| PH (1) | PH12021550166A1 (https=) |
| SG (1) | SG11202012321PA (https=) |
| WO (1) | WO2020021447A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230330054A1 (en) * | 2020-03-31 | 2023-10-19 | Olatec Therapeutics Llc | Method for preventing or treating lung infection and lung inflammation |
| AU2021257619A1 (en) | 2020-04-15 | 2022-12-15 | Janssen Pharmaceutica Nv | Pyrazolo[1,5-d][1,2,4]triazine-5(4H)-acetamides as inhibitors of the NLRP3 inflammasome pathway |
| WO2021209539A1 (en) | 2020-04-15 | 2021-10-21 | Janssen Pharmaceutica Nv | Pyrrolo[1,2-d][1,2,4]triazine-2-yl-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| JP2023523418A (ja) * | 2020-04-23 | 2023-06-05 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｌｒｐ３の阻害剤としての三環式化合物 |
| MX2022013637A (es) * | 2020-04-30 | 2022-11-16 | Janssen Pharmaceutica Nv | Nuevos compuestos de triazinoindol. |
| AU2021279305A1 (en) | 2020-05-28 | 2023-02-09 | Janssen Pharmaceutica Nv | Compounds |
| MX2022014709A (es) | 2020-06-19 | 2022-12-16 | Ac Immune Sa | Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3). |
| TWI911262B (zh) * | 2020-08-14 | 2026-01-11 | 美商戴納立製藥公司 | 化合物、組合物及方法 |
| US20240043450A1 (en) | 2020-09-24 | 2024-02-08 | Janssen Pharmaceutica Nv | New compound |
| EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
| CN114478537B (zh) * | 2020-11-13 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 环酰胺并环化合物及其医药用途 |
| IL302906A (en) * | 2020-11-20 | 2023-07-01 | Denali Therapeutics Inc | Compounds, compositions, and methods |
| CN116964052A (zh) * | 2021-03-04 | 2023-10-27 | 詹森药业有限公司 | 调节nlrp3的4-氨基-6-氧代-哒嗪衍生物 |
| MX2023010310A (es) * | 2021-03-04 | 2023-09-12 | Janssen Pharmaceutica Nv | Derivados de 4-alcoxi-6-oxo-piridazina que modulan nlrp3. |
| CN113230240B (zh) * | 2021-03-22 | 2022-12-27 | 广州医科大学 | 1,3-二苯基丙-2-烯-1-酮衍生物及其应用 |
| CA3215235A1 (en) * | 2021-04-13 | 2022-10-20 | Sharon KLIER | Methods of treating retinal vasculopathies |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| WO2022229315A1 (en) * | 2021-04-29 | 2022-11-03 | Janssen Pharmaceutica Nv | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| CA3166147A1 (en) | 2021-06-23 | 2022-12-23 | Yoda Pharmaceuticals Inc. | Benzimidazole derivatives for treatment and/or prevention of diseases and disorders mediated by nlrp3 |
| CN117545757A (zh) | 2021-07-01 | 2024-02-09 | 詹森药业有限公司 | 5-氧代-吡啶并[2,3-d]哒嗪-6(5H)-基乙酰胺 |
| CN117940120A (zh) * | 2021-07-16 | 2024-04-26 | 戴纳立制药公司 | 化合物、组合物和方法 |
| WO2023028536A1 (en) * | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| CN118302170A (zh) * | 2021-09-17 | 2024-07-05 | 尼科治疗有限公司 | 化合物、组合物和方法 |
| KR20230066899A (ko) | 2021-11-08 | 2023-05-16 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| CN118541366A (zh) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| CN116375728B (zh) * | 2021-12-31 | 2025-06-10 | 成都赜灵生物医药科技有限公司 | 噻吩吡咯并三嗪酮类化合物及其用途 |
| US20250145592A1 (en) * | 2022-02-16 | 2025-05-08 | Nico Therapeutics, Inc. | Compounds, compositions, and methods |
| JP2025506729A (ja) * | 2022-02-21 | 2025-03-13 | サノフイ | チエノピロロトリアジン化合物、それらの調製及びそれらの治療的使用 |
| JP2025524640A (ja) | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| CA3261365A1 (en) | 2022-07-28 | 2024-02-01 | Ac Immune Sa | NEW COMPOUNDS |
| JP2025526692A (ja) * | 2022-08-10 | 2025-08-15 | 武田薬品工業株式会社 | 複素環式化合物 |
| KR20240022938A (ko) | 2022-08-12 | 2024-02-20 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| IL319619A (en) | 2022-09-23 | 2025-05-01 | Merck Sharp & Dohme Llc | Phthalazine derivatives used as NOD-LIKE PROTEIN 3 receptor inhibitors |
| CN120569372A (zh) | 2023-01-24 | 2025-08-29 | 第一三共株式会社 | 经取代的苯化合物 |
| PE20252770A1 (es) * | 2023-03-17 | 2025-12-22 | Ventus Therapeutics U S Inc | Derivados de amida para inhibir nlrp3 y usos de estos |
| KR20260027946A (ko) | 2023-06-02 | 2026-03-03 | 머크 샤프 앤드 돔 엘엘씨 | Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클 |
| WO2025046419A1 (ko) | 2023-08-25 | 2025-03-06 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| TW202532066A (zh) | 2023-12-14 | 2025-08-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之氮雜吲唑衍生物 |
| US20250195511A1 (en) | 2023-12-14 | 2025-06-19 | Merck Sharp & Dohme Llc | Indazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| WO2026024770A1 (en) * | 2024-07-23 | 2026-01-29 | New York Blood Center, Inc. | Compounds for treatment of hemolysis- and inflammasome-associated diseases |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
| WO2010128152A1 (en) | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| BR112012008924A2 (pt) | 2009-10-20 | 2019-09-24 | Novartis Ag | derivado de glicosídeo e usos do mesmo |
| MX342164B (es) | 2010-06-23 | 2016-09-19 | Hanmi Science Co Ltd | Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa. |
| MX336875B (es) | 2010-08-10 | 2016-02-04 | Celgene Avilomics Res Inc | Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk). |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| MX354412B (es) | 2011-06-10 | 2018-03-05 | Merck Patent Gmbh | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US9199997B2 (en) | 2011-11-29 | 2015-12-01 | Ono Pharmaceutical Co., Ltd. | Purinone derivative hydrochloride |
| US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
| SI2892900T1 (en) | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| SG11201503697TA (en) | 2012-11-28 | 2015-06-29 | Intercept Pharmaceuticals Inc | Treatment of pulmonary disease |
| UY35368A (es) | 2013-03-08 | 2014-10-31 | Irm Llc | Péptidos y composiciones para el tratamiento de daño articular |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| KR102350357B1 (ko) | 2013-11-05 | 2022-01-14 | 노파르티스 아게 | 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| CN105979948A (zh) | 2013-12-05 | 2016-09-28 | 安塞塔制药公司 | Pi3k抑制剂和btk抑制剂的治疗组合 |
| NZ719169A (en) | 2013-12-20 | 2018-08-31 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
| WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| DK3143026T3 (da) | 2014-05-13 | 2024-09-30 | Novartis Ag | Forbindelser og sammensætninger til induktion af chondrogenese |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| PE20190710A1 (es) | 2014-10-24 | 2019-05-17 | Bristol Myers Squibb Co | Compuestos de indol carboxamida utiles como inhibidores de cinasas |
| PT3236953T (pt) | 2014-12-24 | 2021-01-29 | Principia Biopharma Inc | Dosagem específica de sítio de um inibidor de btk |
| UA124090C2 (uk) | 2015-06-03 | 2021-07-21 | Прінсіпіа Байофарма Інк. | Інгібітори тирозинкінази |
| US20180282310A1 (en) | 2015-06-10 | 2018-10-04 | Biogen Ma Inc. | Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase |
| JP6889494B2 (ja) | 2015-10-09 | 2021-06-18 | エイシア セラピューティクス， インコーポレイテッド | ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法 |
| PL3371165T3 (pl) | 2015-11-04 | 2022-05-02 | Merck Patent Gmbh | Inhibitor btk do zastosowania w terapii rakowej |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| RU2728827C2 (ru) | 2016-01-05 | 2020-07-31 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения |
| KR20180134395A (ko) * | 2016-04-19 | 2018-12-18 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| KR101865120B1 (ko) | 2016-06-29 | 2018-06-08 | 숭실대학교 산학협력단 | 테스트 노드 기반의 무선 측위 방법 및 그 장치 |
| CN115054586B (zh) | 2016-06-29 | 2024-08-02 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| GB201712282D0 (en) | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| WO2019034693A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
-
2019
- 2019-07-23 KR KR1020217001895A patent/KR20210038877A/ko not_active Withdrawn
- 2019-07-23 JP JP2021503752A patent/JP7555327B2/ja active Active
- 2019-07-23 MA MA053388A patent/MA53388A/fr unknown
- 2019-07-23 AU AU2019309727A patent/AU2019309727B2/en not_active Ceased
- 2019-07-23 BR BR112021000964-7A patent/BR112021000964A2/pt not_active Application Discontinuation
- 2019-07-23 SG SG11202012321PA patent/SG11202012321PA/en unknown
- 2019-07-23 CR CR20210045A patent/CR20210045A/es unknown
- 2019-07-23 CN CN201980047047.4A patent/CN112424207B/zh active Active
- 2019-07-23 US US17/259,252 patent/US12168012B2/en active Active
- 2019-07-23 CA CA3103943A patent/CA3103943A1/en active Pending
- 2019-07-23 JO JOP/2021/0017A patent/JOP20210017A1/ar unknown
- 2019-07-23 EP EP19769892.1A patent/EP3827008B1/en active Active
- 2019-07-23 CU CU2021000009A patent/CU20210009A7/es unknown
- 2019-07-23 MX MX2021000925A patent/MX2021000925A/es unknown
- 2019-07-23 PE PE2021000092A patent/PE20210406A1/es unknown
- 2019-07-23 WO PCT/IB2019/056278 patent/WO2020021447A1/en not_active Ceased
-
2021
- 2021-01-21 PH PH12021550166A patent/PH12021550166A1/en unknown
- 2021-01-21 IL IL280336A patent/IL280336A/en unknown
- 2021-01-22 EC ECSENADI20214787A patent/ECSP21004787A/es unknown
- 2021-01-22 DO DO2021000019A patent/DOP2021000019A/es unknown
- 2021-01-22 CL CL2021000191A patent/CL2021000191A1/es unknown
- 2021-01-22 CO CONC2021/0000537A patent/CO2021000537A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210038877A (ko) | 2021-04-08 |
| ECSP21004787A (es) | 2021-03-31 |
| WO2020021447A1 (en) | 2020-01-30 |
| BR112021000964A2 (pt) | 2021-04-20 |
| CA3103943A1 (en) | 2020-01-30 |
| MA53388A (fr) | 2021-06-02 |
| MX2021000925A (es) | 2021-03-31 |
| CN112424207A (zh) | 2021-02-26 |
| JP7555327B2 (ja) | 2024-09-24 |
| PH12021550166A1 (en) | 2021-09-13 |
| US12168012B2 (en) | 2024-12-17 |
| EP3827008A1 (en) | 2021-06-02 |
| JOP20210017A1 (ar) | 2021-01-21 |
| CN112424207B (zh) | 2024-03-19 |
| CL2021000191A1 (es) | 2021-08-20 |
| DOP2021000019A (es) | 2021-02-15 |
| EP3827008B1 (en) | 2024-07-31 |
| CU20210009A7 (es) | 2021-08-06 |
| AU2019309727B2 (en) | 2021-12-23 |
| CO2021000537A2 (es) | 2021-01-29 |
| AU2019309727A1 (en) | 2021-01-07 |
| JP2021532124A (ja) | 2021-11-25 |
| US20210308140A1 (en) | 2021-10-07 |
| CR20210045A (es) | 2021-06-18 |
| IL280336A (en) | 2021-03-01 |
| SG11202012321PA (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210406A1 (es) | Inhibidores de inflamasoma nlrp3 | |
| PE20221038A1 (es) | Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores | |
| PE20211918A1 (es) | Derivados de tetrahidro-imidazo[4,5-c]piridin como inmunomoduladores de pd-l1 | |
| PE20161292A1 (es) | Compuestos de nicotinamida sustituida con heteroarilo | |
| PE20220578A1 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
| PE20211807A1 (es) | Derivados de pirazina fusionados como inhibidores de a2a/a2b | |
| AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
| PE20051061A1 (es) | 5,7-DIAMINOPIRAZOLO[4,3-d] PIRIMIDINAS | |
| PE20110852A1 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
| AR080779A1 (es) | Pirrolopirazina como inhibidores quinasa, composiciones farmaceuticas que los contienen y sus aplicaciones | |
| PE20160560A1 (es) | DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK) | |
| PE20212186A1 (es) | Inhibidores de la via de jak1 para el tratamiento de trastornos relacionados con citoquinas | |
| PE20040197A1 (es) | Pirazolopiridinas sustituidas con carbamato | |
| AR083058A1 (es) | Compuestos de estructura de imidazotriazinona | |
| PE20211066A1 (es) | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos | |
| PE20130602A1 (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a | |
| CY1110676T1 (el) | ΠΥΡΑΖΟΛΟ[3,4-b]ΠΥΡΙΔΙΝΙΚΕΣ ΕΝΩΣΕΙΣ, ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ | |
| PE20211388A1 (es) | Compuestos |